| P2093 | author name string | K. M. Kessler | |
| P2860 | cites work | Lidocaine Pharmacokinetics in Advanced Heart Failure, Liver Disease, and Renal Failure in Humans | Q34216672 |
| | Biochemical and genetic factors regulating dilantin metabolism in man. | Q39866492 |
| | Pharmacogenetics: defective enzymes in relation to reactions to drugs | Q39868133 |
| | Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients | Q42239557 |
| | Diphenylhydantoin Metabolism in Uremia | Q43563484 |
| | Intramuscularly and orally administered lidocaine in the treatment of ventricular arrhythmias in acute myocardial infarction | Q43943826 |
| | Inhibition of diphenylhydantoin metabolism by chloramphenicol | Q43983201 |
| | The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man | Q45000191 |
| | The rate of decline of diphenylhydantoin in human plasma | Q46365064 |
| | Interaction between phenobarbital and diphenylhydantoin in animals and in epileptic patients | Q48805544 |
| | DIPHENYLHYDANTOIN METABOLISM, BLOOD LEVELS, AND TOXICITY. | Q52134645 |
| | Identification of glycinexylidide in patients treated with intravenous lidocaine | Q52731906 |
| | Plasma levels of lidocaine after intramuscular administration. | Q52734863 |
| | Disposition kinetics of lidocaine in normal subjects. | Q52737564 |
| | Interaction between phenytoin and the benzodiazepines | Q52739204 |
| | Interrelationships of Hepatic Blood Flow, Cardiac Output, and Blood Levels of Lidocaine in Man | Q52739325 |
| | Acute diphenylhydantoin intoxication following halothane anesthesia. | Q52741995 |
| | Effect of Lidocaine on Ventricular Arrhythmias in Patients with Coronary Heart Disease | Q52755082 |
| | Acute intoxication with 5,5-diphenylhydantoin (Dilantin) associated with impairment of biotransformation. Plasma levels and urinary metabolites; and studies in healthy volunteers. | Q53694232 |
| | Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. | Q53755058 |
| | Metabolism of procainamide in rhesus monkey and man | Q53778339 |
| | Procainamide Dosage Schedules, Plasma Concentrations, and Clinical Effects | Q56474598 |
| | Relation between serum quinidine levels and renal function. Studies in normal subjects and patients with congestive failure and renal insufficiency | Q57226563 |
| | Inhibition of drug metabolism by chloramphenicol | Q67211676 |
| | Abnormal pharmacokinetics of phenytoin in a patient with uraemia | Q67239346 |
| | Hypotension due to 5 per cent plasma protein fractions | Q67265847 |
| | Copper deficiency in a premature infant fed on iron-fortified formula | Q67265862 |
| | Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution | Q68749158 |
| | Influence of disease on binding of drugs to plasma proteins | Q69035369 |
| | Intermittent intravenous procaine amide to treat ventricular arrhythmias. Correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure | Q69471761 |
| | Plasma diphenylhydantoin values after oral and intramuscular administration of diphenylhydantoin | Q69578887 |
| | Quinidine Elimination in Patients with Congestive Heart Failure or Poor Renal Function | Q69737872 |
| | The effect of phenyramidol on the metabolism of diphenylhydantoin | Q69973842 |
| | Intoxication with 5,5-diphenylhydantoin (Dilantin): clinical features, blood levels, urinary metabolites, and metabolic changes in a child | Q70342021 |
| | Pharmacodynamics of Propranolol in Renal Failure | Q70388191 |
| | Drug therapy. Serum drug concentrations as therapeutic guides | Q70402681 |
| | Pharmacokinetics of Procainamide | Q70442540 |
| | Pharmacokinetics of lidocaine in man | Q70548407 |
| | Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants | Q70560587 |
| | Pharmacokinetic of procainamide in man | Q71065194 |
| | Quinidine Excretion in Aciduria and Alkaluria | Q71261521 |
| | Comparison of two methods for quinidine determination and chromatographic analysis of the difference | Q72338401 |
| | Metabolic disposition of diphenylhydantoin in normal human subiects following intravenous administration | Q72409480 |
| | Some Causes of Ineffectiveness of Diphenylhydantoin | Q72779762 |
| | Depression of parahydroxylation of diphenylhydantoin by antituberculosis chemotherapy | Q72877695 |
| | Serum quinidine concentration in congestive heart failure | Q73042221 |
| | Studies of quinidine plasma levels and rate of decline following cessation of quinidine administration | Q73383907 |
| | Quinidine concentration in blood and excretion in urine following parenteral administration as related to congestive heart failure | Q74771489 |
| | INSUFFICIENT PARAPHYDROXYLATION AS A CAUSE OF DIPHENYLHYDANTOIN TOXICITY | Q76847009 |
| | DIPHENYLHYDANTOIN AND PHENOBARBITAL TOXICITY. THE ROLE OF LIVER DISEASE | Q76935999 |
| | SOME CELLULAR AND METABOLIC CONSIDERATIONS RELATING TO THE ACTION OF QUINIDINE AS A PROTOTYPE ANTIARRHYTHMIC AGENT | Q77104707 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1019-1026 | |
| P577 | publication date | 1974-09-01 | |
| P1433 | published in | Medical Clinics of North America | Q15761972 |
| P1476 | title | Individualization of Dosage of Antiarrhythmic Drugs | |
| P478 | volume | 58 | |